Dr. Adam Levine discusses Ebola on CNN's State of the Union with Candy Crowley
-
Wednesday, 1st October
Liberia Identifies Ebola Patient Who Flew to Texas
-
Wednesday, 1st October
Home | Global Health eLearning Center
-
Wednesday, 1st October
Why Big Data Missed the Early Warning Signs of Ebola
Ebola and Global Health Governance: Time for the Reckoning
-
Sunday, 28th September
WHO sees small-scale use of experimental Ebola vaccines in January
-
Saturday, 27th September
Video: Dying of Ebola at the Hospital Door
-
Tuesday, 16th September
Epidemiology of Emergency Patients in Gaborone, Botswana
-
Monday, 15th September

pubhealth:

Reinvent the Toilet | India

We need a toilet revolution—new ideas to help reduce disease and find new ways to turn crap into valuable stuff, like fuel, fertilizer, and fresh water.

(From Bill & Melinda Gates Foundation)

Cuts at WHO Hurt Ebola Response
-
Thursday, 11th September
New test fast-tracks diagnosis for malaria
-
Wednesday, 10th September
Replace short-term medical missions with long-term local investment
-
Tuesday, 9th September
WHO publishes first global report on topic “shrouded in taboo”: Suicide
-
Monday, 8th September
pubhealth:

First Vaccine for Dengue Fever Shows Promise in 2nd Big Trial
By Andrew Pollack
An experimental vaccine against dengue fever being developed by Sanofi proved about 60 percent effective in its second large clinical trial. The results could clear the way for the introduction of the world’s first inoculation against the disease, which is mosquito-borne and becoming an increasing threat.
Sanofi, a French drug company, said on Wednesday that use of the vaccine cut the risk of getting dengue by 60.8 percent in the trial, which involved 20,875 children ages 9 to 16 from several countries in Latin America and the Caribbean.
Those who received the vaccine also had an 80.3 percent lower risk of being hospitalized for dengue compared with children who received injections of a placebo.
The results are roughly similar to those from the first large clinical trial, in which the vaccine reduced the incidence of dengue fever by 56.5 percent. That trial involved about 10,000 children in Southeast Asia.
“For the first time ever, after 20 years of research and industrial commitment, dengue is set to become a vaccine-preventable disease,” Olivier Charmeil, chief executive of Sanofi Pasteur, the vaccine division of Sanofi, said in a statement.
(More from The New York Times)

pubhealth:

First Vaccine for Dengue Fever Shows Promise in 2nd Big Trial

By Andrew Pollack

An experimental vaccine against dengue fever being developed by Sanofi proved about 60 percent effective in its second large clinical trial. The results could clear the way for the introduction of the world’s first inoculation against the disease, which is mosquito-borne and becoming an increasing threat.

Sanofi, a French drug company, said on Wednesday that use of the vaccine cut the risk of getting dengue by 60.8 percent in the trial, which involved 20,875 children ages 9 to 16 from several countries in Latin America and the Caribbean.

Those who received the vaccine also had an 80.3 percent lower risk of being hospitalized for dengue compared with children who received injections of a placebo.

The results are roughly similar to those from the first large clinical trial, in which the vaccine reduced the incidence of dengue fever by 56.5 percent. That trial involved about 10,000 children in Southeast Asia.

“For the first time ever, after 20 years of research and industrial commitment, dengue is set to become a vaccine-preventable disease,” Olivier Charmeil, chief executive of Sanofi Pasteur, the vaccine division of Sanofi, said in a statement.

(More from The New York Times)

-
Monday, 8th September
Latin America Has No Antibodies to Fight Chikungunya Fever